Pillar Biosciences and Collaborators to Present NGS Data Across Solid Tumors, Liquid Biopsy, and Heme Malignancies at 2026 Association for Molecular Pathology (AMP) Annual Meeting

NATICK, Mass., Oct. 15, 2026 /PRNewswire/ -- Pillar Biosciences today announced that ten scientific posters featuring their NGS technology will be presented, including a platform presentation at the 2026 Association for Molecular Pathology (AMP) Annual Meeting & Expo in Seattle, WA, November 10-14. Pillar will also host three corporate workshop presentations during which laboratory leaders from Duke University Medical Center, the European Institute of Oncology, and the University of Pennsylvania Health System will share their own experience with Pillar's rapid NGS panels. The research spans data generated on liquid biopsy, solid tumor profiling, lymphoid malignancies, measurable residual disease in acute myeloid leukemia (AML), and automated NGS library preparation. Academic and industry collaborators presenting their work include Duke University Medical Center, Memorial Sloan Kettering Cancer Center, the University of Pennsylvania Health System, the European Institute of Oncology, Labcorp, Advocate Health, Genotypos, and Hamilton Company.

"Laboratories' need for rapid NGS has expanded steadily, from tissue-based tumor profiling to hematologic malignancies, and now to liquid biopsy and residual disease monitoring," said Dan Harma, Chief Commercial Officer of Pillar Biosciences. "This year's posters, most of them presented by our collaborators, show laboratories bringing rapid, local NGS into each of these areas, from ESR1 testing in plasma to MRD assessment in AML. We're grateful to the cancer centers and laboratories sharing their work, and we'll keep working to make precise, accessible NGS a front-line tool in precision oncology."

Pillar Biosciences Corporate Workshops

Wednesday, November 11th

1. "Evaluation and Analytical Validation of a Rapid NGS Panel to Evaluate Lymphoid Malignancies" – Sarah Rapisardo, Ph.D., FACMG, and Barbara Anderson, Ph.D., Duke University Medical Center (8:00-8:50 AM, Skagit 3, Lower Level, Arch at 800 Pike)
2. "Bringing Liquid Biopsy Closer to Patients: Rapid Local NGS Testing for Biomarker Assessment in Advanced Breast Cancer" – Konstantinos Venetis, Ph.D., European Institute of Oncology (IEO) IRCCS (9:00-9:50 AM, Skagit 3, Lower Level, Arch at 800 Pike)
3. "Rapid NGS That Scales: Clinical Implementation of oncoReveal® Myeloid NGS on the MiSeq i100" – Sarah Herlihy, Ph.D., and AmandaSue Landi, M.S., University of Pennsylvania Health System (10:00-10:50 AM, Skagit 3, Lower Level, Arch at 800 Pike)

Platform Presentations

Saturday, November 14^th 

1. MiSeq i100 Plus and oncoReveal Myeloid: Efficient NGS Detection of Actionable AML Variants, Including FLT3-ITDs – Li Bian, Advocate Clinical Laboratories (1:30-1:45 PM, 606-607, Level 6, Arch at 705 Pike- H065)

Scientific Poster Presentations Featuring Pillar Biosciences Technology

Friday, November 13th (9:15-10:15 AM PT)

1. Inferring Copy Number Variations from a Targeted Amplicon Liquid Biopsy Panel Without Run-Matched Baseline Controls – Pillar Biosciences (I062)
2. Using High-Efficiency Low-Input Amplicon Chemistry and Informatics Strategies to Improve Molecular Testing in Prostate Tissue Samples – Pillar Biosciences (ST122)
3. An Integrated DNA/RNA Amplicon Panel for Rapid Multi-Cancer Genomic Profiling of Actionable Biomarkers in Solid Tumors – Pillar Biosciences (ST030)
4. ctDNA ESR1 and Multi-Gene Testing by NGS versus ddPCR in Metastatic Breast Cancer – Genotypos (ST072)
5. Assessment of a Targeted Next-Generation Sequencing Assay for Detecting NPM1 and FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia – Memorial Sloan Kettering Cancer Center (H044)
6. Utilizing Read Depth as a Rapid Screening Tool for Detecting Copy Number Gains in MSK-REACT – Memorial Sloan Kettering Cancer Center (ST140)
7. Preparing Molecular Pathology Laboratories for the ESR1 Interception Era: Defining Analytical Requirements for Plasma Testing in HR+/HER2– Metastatic Breast Cancer – European Institute of Oncology (IEO) (ST118)

Saturday, November 14th (9:15-10:15 AM PT)

1. Development and Validation of an Automation Method Pillar Biosciences OncoReveal® Nexus 21 Gene Panel on the Hamilton Microlab® NGS STAR MOA and STARlet Instruments – Hamilton (TT043)
2. MiSeq i100 Plus and OncoReveal Myeloid: Efficient NGS Detection of Actionable AML Variants, Including FLT3-ITDs – Advocate Health (H065)
3. Evaluation of a Rapid AML NGS Assay – Labcorp (ST145)

About Pillar Biosciences

Pillar Biosciences is a global provider of next-generation sequencing (NGS) kitted solutions designed to deliver high analytical performance and operational efficiency for cancer testing. Powered by proprietary SLIMamp® and PiVAT® technologies, Pillar enables localized testing to expand access to complex molecular diagnostics worldwide. The company offers a growing portfolio of IVD and RUO NGS kits for tumor profiling, biomarker analysis, and molecular research and monitoring applications. For more information, visit pillarbiosci.com and connect with us on LinkedIn.

SOURCE Pillar Biosciences, Inc.